Brokerage Calls Today: L&T, Tech Mahindra, Lupin, ABB, Coforge Targets
Ahead of the opening bell on Dalal Street on Wednesday, November 18, 2026, leading global institutional brokerages—including CLSA, JPMorgan, Nomura, Macquarie, and HSBC—rolled out a comprehensive slate of stock-specific ratings, target price revisions, and sector outlooks spanning more than 20 frontline and mid-cap companies. Covering high-conviction themes across capital goods, information technology, pharmaceuticals, electronics manufacturing services (EMS), real estate, paints, healthcare, steel, and consumer electricals, the notes give market participants an actionable roadmap amid shifting global cues. Among the standout individual calls, CLSA reiterated bullish Outperform ratings on infrastructure bellwether Larsen & Toubro (L&T) with a target price of ₹4,842—citing a tenfold expansion plan in AI factories and data center capacity alongside a second-half FY27 execution pickup—and Coforge with a High Conviction Outperform tag and ₹2,522 target driven by synergies from its Encora acquisition. In large-cap IT, JPMorgan maintained an Overweight stance on Tech Mahindra with a ₹1,900 target, pointing to steady deal-win momentum and gradual margin expansion toward FY27 goals, whereas CLSA struck a more measured tone on HCL Technologies with a Hold rating and ₹1,094 target due to potential AI-led pricing compression across legacy portfolios. Meanwhile, Macquarie upgraded ABB India to Neutral with a ₹7,100 target after third-quarter new orders jumped 56 percent to ₹4,700 crore and its order backlog climbed 36 percent, while Nomura reaffirmed a Buy on Lupin at a ₹2,780 target, arguing that U.S. trade concerns are largely priced in ahead of upcoming specialty launches. In the EMS space, Syrma SGS Technology earned a Buy rating and ₹2,000 target backed by a ₹7,400 crore order book and a $1 billion revenue goal by FY2028, while CLSA backed JSW Steel (₹1,500) and Havells India (₹1,290) with Outperform calls. Complementing single-stock notes, HSBC laid out multi-year sector blueprints favoring Godrej Properties, DLF, Prestige Estates, Oberoi Realty, and Sobha in real estate, Pidilite over Asian Paints and Berger Paints in building materials, and Apollo Hospitals, Aster DM, Torrent Pharma, and Glenmark Pharma in healthcare. For retail investors, portfolio managers, and traders across Mumbai, New Delhi, Ahmedabad, Bengaluru, Chennai, Hyderabad, Kolkata, and Lucknow, these institutional calls highlight where earnings visibility and capital expenditure tailwinds remain strongest.
Stock-by-Stock Brokerage Recommendations and Target Prices
The table below consolidates the key brokerage ratings, target prices, and core investment theses issued across individual stocks ahead of Wednesday's trading session:
| Company / Stock | Brokerage House | Rating / Action | Target Price | Key Investment Rationale & Catalysts |
| Larsen & Toubro (L&T) | CLSA | Outperform | ₹4,842 | Execution momentum expected to accelerate in H2 FY27; strong order book bolstered by 10x expansion target in AI factories and data centers, EVs, power, and energy security. |
| Coforge | CLSA | High Conviction Outperform | ₹2,522 | Incremental revenue accretion from the Encora acquisition alongside strong wallet-share expansion across new and existing enterprise clients. |
| Tech Mahindra | JPMorgan | Overweight | ₹1,900 | Improving growth trajectory supported by large deal wins and new business; on track for FY27 revenue and gradual margin recovery targets. |
| HCL Technologies | CLSA | Hold | ₹1,094 | Strong full-stack AI capabilities across services, software, engineering, and data centers, but AI-driven pricing pressure on core services may cap near-term revenue growth. |
| ABB India | Macquarie | Upgraded to Neutral | ₹7,100 | Q3 revenue rose 19%, EBITDA 14%, and profit 8% (margin dipped 70 bps to 14.8%); new orders surged 56% to ₹4,700 crore and order backlog jumped 36%. |
| Lupin | Nomura | Buy | ₹2,780 | U.S. trade headwinds largely discounted in current valuations; strong domestic formulation growth, healthy balance sheet, and new drug launches offer a 1–2 year entry window. |
| Syrma SGS Technology | Brokerage Consensus / Note | Buy | ₹2,000 | Robust ₹7,400 crore order book (₹6,200 crore executable over 12 months); added 32 new clients (15 in autos); targets 30–35% EBITDA growth and $1B revenue by FY28. |
| JSW Steel | CLSA | Outperform | ₹1,500 | Major capacity expansion underway alongside targeted cost savings of ~₹2,000 per tonne over three years, though elevated Chinese steel exports remain a key monitorable. |
| Havells India | CLSA | Outperform | ₹1,290 | Focus on core electrical categories, selective price hikes, and potential raw-material cost softening expected to drive double-digit medium-term growth across verticals. |
HSBC Sector Deep Dive: Real Estate, Paints, and Healthcare Picks
Alongside individual stock targets, HSBC published detailed thematic assessments across three major domestic consumption and infrastructure sectors:
-
Real Estate (Two-Phase Upswing in 2027): HSBC projects Indian housing developers to experience two distinct growth phases in 2027, propelled by major project launches, strong project deliveries, improving operating cash flows, returning foreign institutional inflows, and steady domestic institutional confidence. Its top Buy picks are Godrej Properties, DLF, Prestige Estates, Oberoi Realty, and Sobha.
-
Paints & Adhesives (Margin Pressure vs. Adjacent Growth): While underlying decorative paint demand remains steady, HSBC noted that consumption of higher-cost legacy inventory and adverse product-mix shifts are weighing on near-term margins. Rapid expansion in waterproofing and tile adhesives underpins HSBC's reiterated Buy on Pidilite Industries, while it maintained Hold ratings on Asian Paints and Berger Paints.
-
Healthcare & Pharma (Capacity Expansion & Launches): Finding Q2 earnings broadly in line with estimates, HSBC highlighted hospital bed additions and specialty product pipelines as primary growth drivers, naming Apollo Hospitals, Aster DM Healthcare, Torrent Pharmaceuticals, and Glenmark Pharmaceuticals as its preferred sectoral bets.
Investor Takeaway: Balancing Domestic Capex Themes Against Global Volatility
Taken together, Wednesday's institutional research underscores a clear preference for companies backed by tangible order backlogs, domestic infrastructure spending, and specialty manufacturing—such as L&T, ABB India, Syrma SGS, JSW Steel, and leading real-estate developers—while urging selectivity in export-exposed IT and margin-sensitive consumer plays. Investors should weigh these target prices against their individual risk appetite, valuation comfort, and broader market volatility before making portfolio decisions.